BioCentury
DATA GRAPHICS | Data Byte

Ten PD-1 mAbs approved worldwide

Six anti-PD-1 mAbs originating at Chinese biopharmas join the four from the U.S. and Japan on the market

October 23, 2021 1:40 AM UTC

Since the 2014 approval of Keytruda pembrolizumab and Opdivo nivolumab, competition among mAbs targeting PD-1 has become fierce. At least 10 products are now approved globally, with six originating from companies in China. All but one of those Chinese products has found a global marketing partner, and three of them are under FDA review. ...